Intravenous infusion procedures incur minimal downtime; patients resume normal activities within 24 hours. Systemic symptoms (mild fever, transient arthralgia) occur in <10% and resolve within 1 week. Skin changes (transient erythema, scaling exacerbation) may briefly flare before improvement; this is typically self-limited (days to 1 week). Clinical plateau is reached by 12 weeks; extended follow-up (6–12 months) documents remission durability.
Clinical trial data spans phase I safety and small phase II efficacy assessments involving 50–200 participants per study. Representative trials report psoriasis area and severity index (PASI) improvements of 50% or greater in 35–50% of infused cohorts over 12 weeks, with some achieving PASI 75 or 90 (near-complete clearance) in 20–30%. Erythema, scaling, and infiltration scores improve more consistently than pruritus. Remission duration in responders extends 3–8 months post-infusion; re-treatment may be required for sustained control. Compared to anti-TNF or anti-IL-17 biologics, MSC efficacy appears modest but comparable in blinded assessments.
Sunt un candidat? → · Psoriasis: full overview → · Cost Psoriază → · Cost →
Revizuit medical de echipa editorială a StemCellAtlas cu Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) ale clinicii partenere Stem Plus (Sofia), în funcție de orientările ISSCR, FDA și EMA. Educational information, not medical advice; figures indicative.
Medicină regenerativă certificată GMP în inima UE — de la 3.000–8.000 €, o fracțiune din prețurile din SUA sau Germania. Protocoale personalizate pentru pacienți din peste 50 de țări.
Evaluare medicală gratuită